Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07643038 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment Strategy for Patients With RA-ILD

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jul 1, 2026 to Sep 20, 2026
    • Interventions modified
    • Secondary endpoints: details revised at 1 of 6 entries
    • Study description revised
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a 52-week, multicenter, prospective, open-label, randomized controlled clinical study, comparing the efficacy and safety of tocilizumab, rituximab, and csDMARD methotrexate in patients with RA-ILD.
Trial Details
NCT Number NCT07643038
Lead Sponsor Chinese SLE Treatment And Research Group
Conditions
(from sponsor)		 Rheumatoid Arthritis Associated Interstitial Lung Disease
Enrollment 204 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov